Vascugraft microporous polyesterurethane arterial prosthesis as a thoraco-abdominal bypass in dogs

In their progression towards clinical acceptance, any new synthetic vascular grafts under development must undisputedly prove that the chemistry and structure used in the construction of the prostheses is safe and that their biocompatibility and performance as arterial substitutes are satisfactory without degradation or weakening of the device. This study was conducted to evaluate the safety of the microporous polyesterurethane Vascugraft by investigating its biocompatibility in terms of cellular proliferation, morphology and adhesion of human fibroblasts on virgin and blood-soaked Vascugraft prostheses, and its performance in vivo as a large calibre graft in a canine thoraco-abdominal bypass model for periods of implantation ranging from 4 h to 6 months. After 3 d incubation, better cell proliferation and adhesion were observed on blood-soaked Vascugraft than on a non-porous polyurethane graft, Mitrathane, and two other polytetrafluorethylene prostheses, Impra and Goretex. Furthermore, no leachable cytotoxic contaminants were released from the prostheses. In vivo, the Vascugraft has demonstrated a good performance with the development of an endothelialised internal capsule at both anastomoses 2 weeks after implantation, reaching the medial portion of the graft at 4 months. During this period, the prostacyclin I2/thromboxane A2 ratio increased and was higher than 1.0 at 2 months. In addition, the Vascugraft exhibited low surface thrombogenicity in terms of radiolabelled platelets and fibrin deposited. Chemically, as revealed by ESCA and FTIR analyses, a slight decrease in carbonate content was observed on the external surface of the Vascugraft during the early post-implantation periods. Breaks in the microfibrous structure were also observed at 4 and 6 months, occurring mainly in the anastomotic regions and believed to be stress-related. This study shows that the polymer used in the Vascugraft is biocompatible in terms of fibroblast proliferation and promotes fair healing characteristics. However, the chemical and structural surface modifications noted in this study are disturbing and question the total inocuity of the Vascugraft. Consequently, the decision by B. Braun Melsungen AG to end this project is both highly conscientious and professional.